Enhanced brain uptake of biologics
Affilogic is developing a Nanofitin®–based shuttle for brain delivery of nucleic acid therapies
The mechanism of action relies on receptor-mediated transcytosis, and Affilogic has developed Nanofitins® against a receptor of the Blood-Brain-Barrier, the transferrin receptor (TfR), that have been evaluated in vitro and in vivo in relevant models, with partners (Laboratoire de la Barrière Hémato-Encéphalique – Artois University, Samabriva).
Our Nanofitin®-based BBB shuttle is now combined with nucleic acids by regio-selective click chemistry. N-/C- termini of the Nanofitins® not being involved in the binding site, they can be easily conjugated while conserving their specificity and the payload its activity.
Our current program on active brain delivery of oligonucleotides is capitalizing upon our previous work with antibodies, showing very attractive results in-vivo.
Satellite projects :
Monoclonal antibody : We previously evaluated brain delivery of an anti-BACE1 Monoclonal Antibody in vitro and in vivo in mice. We showed significative reduction of AB40 brain concentration in mice treated with our Nanofitin®-antibody fusion, compared to the anti-BACE1 antibody alone, after IV administration.
Enzyme Replacement Therapy : We also worked on brain delivery of acid sphingomyelinase to treat a lysosomal storage disorder, the Niemann-Pick B disease.